Climb Bio Stock Today
| CLYM Stock | 1.51 0.05 3.42% |
PerformanceOK
| Odds Of DistressLow
|
Climb Bio is selling at 1.51 as of the 21st of July 2025; that is 3.42 percent increase since the beginning of the trading day. The stock's lowest day price was 1.45. Climb Bio has less than a 18 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Climb Bio symbol was changed from ELYM on 3rd of October 2024. The performance scores are derived for the period starting the 22nd of April 2025 and ending today, the 21st of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of August 2021 | Category Healthcare | Classification Health Care |
Climb Bio is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 67.58 M outstanding shares of which 1.41 M shares are currently shorted by private and institutional investors with about 14.68 trading days to cover. More on Climb Bio
Moving together with Climb Stock
Moving against Climb Stock
| 0.52 | BCH | Banco De Chile Earnings Call This Week | PairCorr |
Climb Stock Highlights
| Older Symbol | ELYM | |||||||||||||||||||||||||||||||||||
| President CEO | BAO BCh | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsClimb Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Climb Bio's financial leverage. It provides some insight into what part of Climb Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Climb Bio (CLYM) is traded on NASDAQ Exchange in USA. It is located in 20 William Street, Wellesley Hills, MA, United States, 02481 and employs 17 people. Climb Bio was previously known as ELYM Old and was traded on NASDAQ Exchange under the symbol ELYM. Climb Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 85.82 M. Climb Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 67.58 M outstanding shares of which 1.41 M shares are currently shorted by private and institutional investors with about 14.68 trading days to cover.
Climb Bio generates negative cash flow from operations
Check Climb Bio Probability Of Bankruptcy
Ownership AllocationClimb Bio holds a total of 67.58 Million outstanding shares. The majority of Climb Bio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Climb Bio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Climb Bio. Please pay attention to any change in the institutional holdings of Climb Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Climb Ownership Details
Climb Bio Historical Income Statement
Climb Stock Against Markets
Climb Bio Corporate Management
| Chandra JD | VP Counsel | Profile | |
| Jo PalmerPhillips | Chief Officer | Profile | |
| Emily CPA | Senior Officer | Profile | |
| Cindy MBA | Senior Finance | Profile | |
| Emily Pimblett | Chief Officer | Profile | |
| Nishi MD | Senior Development | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.